Day: March 11, 2025

ZenaTech Signs LOI to Acquire Sixth Land Survey Company in Arizona and First in the Southwest Region for Drone as a Service

Written by Customer Service on March 11, 2025. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that it has signed an LOI (Letter of Intent) to acquire a sixth land survey engineering company located in Arizona. Upon completion, this will be the first acquisition in the Southwest Region and will serve as a launchpad to further regional development and the Company’s national DaaS business model bringing the speed and precision of AI drone solutions in a convenient subscription or pay-per-use model for businesses and government users. “Arizona is a strategic location for our first potential Southwest region acquisition as we currently...

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 10 03 2025] – (CGWL)

Written by Customer Service on March 11, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 11, 2025. Posted in Earnings Releases And Operating Results.

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2024. “We started 2025...

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Written by Customer Service on March 11, 2025. Posted in Earnings Releases And Operating Results.

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent HighlightsReached key milestones in the ORCA-OL long-term exposure trial, including completion of enrollment and meeting the requirement of 300 participants receiving six...

The Board of Directors of Harvia Plc have decided on a new performance period for the Long-term Performance Share Plan for the key employees

Written by Customer Service on March 11, 2025. Posted in Public Companies.

Harvia Plc, Stock Exchange Release, New performance period for the Long-term Performance Share Plan, 11 March 2025 at 2:00 p.m EET The Board of Directors of Harvia Plc have decided on a new performance period for the Long-term Performance Share Plan for the key employees The Board of Directors of Harvia Plc has decided on March 10th, 2025 to continue the Long-term Performance Share Plan for the management team and other key employees for the performance period 2025-2027. The plan will form a part of Harvia Plc’s remuneration program for its key employees, and the aim of the Plan is to support the implementation of the company’s strategy, to align the objectives of key employees with the shareholders to increase the value of the company, to improve the performance of the company, and to retain key employees. In the performance period...

Glass House Brands to Host Fourth Quarter and Full Year 2024 Conference Call on March 25, 2025

Written by Customer Service on March 11, 2025. Posted in Public Companies.

LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest-growing, vertically-integrated cannabis companies in the U.S., today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 25, 2025, after market close. The Company will host a conference call to discuss the results at 5:00 p.m. Eastern Time. Participants can find the live webcast here or on the Glass House Brands website at https://glasshousebrands.com/news-events/events-and-webcasts/. The webcast will be archived for approximately 30 days. Participants interested in dialing in can call 1.800.715.9871 or +1.646.307.1963 and...

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Written by Customer Service on March 11, 2025. Posted in Public Companies.

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website. About X4 PharmaceuticalsX4 is delivering...

Kratos Awarded Potential $50 Million Short/Medium Range Sub-Orbital Vehicle II Contract to Support Missile Defense Related Missions

Written by Customer Service on March 11, 2025. Posted in Public Companies.

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security, and global markets, today announced the award of the Short/Medium Range Sub-Orbital Vehicle (SSOV) II contract as a partner to Corvid Technologies, LLC. The contract, awarded by the Naval Surface Warfare Center, Port Hueneme, White Sands Detachment, will encompass the design, manufacture, and delivery of short- and medium-range suborbital vehicles, including provision of ground test hardware, special test equipment, materials, engineering, and launch support services. The contract includes options which, if exercised, bring the potential subcontract value to greater than $50 million. Josh Peterson, Senior Vice President at Kratos Defense & Rocket Support Services,...

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Written by Customer Service on March 11, 2025. Posted in Public Companies.

– Topline data expected as early as mid-2025 – SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. “We are pleased to initiate a Phase 1 trial for our oral bivalent norovirus vaccine, delivered in a pill formulation, which will seek to demonstrate improved immune responses of our second-generation constructs,” said Steven Lo, Chief Executive Officer of Vaxart. “As norovirus continues to spread across the United States and globally, it has never been more important to address this urgent public health need. With no currently approved vaccines against norovirus, we are committed...

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Written by Customer Service on March 11, 2025. Posted in Public Companies.

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the clearance of its Investigational New Drug (IND) application for TVB-3567, the Company’s second fatty acid synthase (FASN) inhibitor. TVB-3567 is a potent and selective small molecule FASN inhibitor, planned to enter clinical development for the treatment of acne. The IND with the U.S. Food and Drug Administration’s Division of Dermatology and Dentistry allows the Company to initiate a first-in-human Phase 1 clinical trial of TVB-3567, planned in 2025. “The...

Day: March 11, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals